Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT06588660 · University of Washington · PHASE1 · terminated · last registry update 2025-07-29 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated due to end of funding.” | Open Targets' class: business administrative | Registry record, University of Washington |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD3E in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-27Phase 3 first posted: AbbVie, Etentamig + Pomalidomide (NCT07728188)
- 2026-06-26Phase 3 first posted: University of Heidelberg Medical Center, Teclistamab + Daratumumab (NCT07671287)
- 2026-06-16Phase 3 first posted: University of Leeds, Daratumumab + Lenalidomide (NCT07649525)
- 2026-04-24Also stopped (terminated): Pfizer, Elranatamab + Nirogacestat + Elranatamab + lenalidomide + dexamethasone (NCT05090566)
- 2026-04-08Phase 3 first posted: Janssen Research & Development, LLC, JNJ-79635322 + Teclistamab (NCT07518186)
- 2026-02-23Results posted on the registry: Pfizer, Elranatamab + Nirogacestat + Elranatamab + lenalidomide + dexamethasone (NCT05090566)
- 2025-12-02Phase 3 first posted: Janssen Research & Development, LLC, JNJ-79635322 + Teclistamab (NCT07258511)
- 2025-08-22Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QLS32015 + Pomalidomide (NCT07138209)
- 2025-04-09Phase 3 first posted: Intergroupe Francophone du Myelome, Elranatamab + Lenalidomide (Revlimid®) (NCT06918002)
- 2024-09-19Results posted on the registry: Pfizer, Elranatamab (NCT05228470)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision